Form 8-K LIGAND PHARMACEUTICALS For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
August 4, 2014 2:24 PM EDTRoth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $92 price target following Q2 results and update issued earlier Monday.
Analyst Joseph Pantginis commented We believe LGND is in its strongest financial position to date with a growing cash balance, debt fully... More
Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook
August 4, 2014 8:40 AM EDTLigand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $9.73 million.
Ligand Pharmaceuticals, Inc. sees Q3 2014 EPS of $0.26-$0.29, versus the consensus of $0.4. Ligand... More
